Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenus
0
0
0
0
0
0
Croissance des revenus (H/H)
--
--
--
--
--
--
Coût des ventes
0
0
0
0
0
0
Bénéfice brut
0
0
0
0
0
0
Vente, Général et Administration
0
0
0
0
0
0
Recherche et développement
--
--
--
--
--
--
Frais d'exploitation
0
0
0
0
0
0
Autres revenus (charges) non opérationnels
0
0
--
--
--
--
Bénéfice avant impôts
0
0
0
0
-1
0
Charge d'impôt sur le revenu
--
--
--
--
--
--
Bénéfice net
0
0
0
0
-1
0
Croissance du bénéfice net
--
--
--
-100%
--
--
Actions en circulation (diluées)
9.53
8.21
3.72
0.7
0.22
20.38
Variation des actions (H-H)
60%
121%
426.99%
214%
-99%
9%
EPS (dilué)
-0.08
-0.1
-0.19
-1.26
-4.67
-0.04
Croissance du EPS
-25%
-43%
-85%
-73%
11,131%
225%
Flux de trésorerie libre
0
0
0
0
0
0
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
0%
0%
0%
0%
0%
0%
Marge opérationnelle
0%
0%
0%
0%
0%
0%
Marge bénéficiaire
0%
0%
0%
0%
0%
0%
Marge du flux de trésorerie libre
0%
0%
0%
0%
0%
0%
EBITDA
0
0
0
0
0
--
Marge EBITDA
0%
0%
0%
0%
0%
--
D&A pour le résultat opérationnel
0
0
0
0
0
--
EBIT
0
0
0
0
0
0
Marge EBIT
0%
0%
0%
0%
0%
0%
Taux d'imposition effectif
--
--
--
--
--
--
Follow-Up Questions
Quels sont les états financiers clés de BioAdaptives Inc ?
Quels sont les ratios financiers clés pour BDPT ?
Comment les revenus de BioAdaptives Inc sont-ils répartis par segment ou géographie ?
BioAdaptives Inc est-elle rentable ?
BioAdaptives Inc a-t-elle des passifs ?
Combien d'actions en circulation BioAdaptives Inc a-t-elle ?
Statistiques clés
Clôture préc.
$0.0161
Prix d'ouverture
$0.0176
Plage de la journée
$0.0176 - $0.0176
Plage de 52 semaines
$0.0131 - $0.1195
Volume
10.0K
Volume moyen
30.8K
BPA (TTM)
-0.09
Rendement en dividend
--
Capitalisation boursière
$212.3K
Qu’est-ce que BDPT ?
BioAdaptives, Inc. engages in marketing, investigating, and distributing natural plant and algal-based products that improve health and wellness for humans and animals. The company is headquartered in Las Vegas, Nevada and currently employs 1 full-time employees. The company went IPO on 2014-07-09. The Company’s core business is to investigate, market and distribute natural plant, fungi, and algal based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products in development include a weight management supplement in a human clinical trial, Zeranovia. Zeranovia is made of natural ingredients and uses proprietary methods of optimizing the availability of nutrients in foods and beverages. Xcellara regenerative stem cell activator is in production. Xcellara is its regenerative wellness solution, to enhance performance, accelerate recovery, and revitalize health. PawPa Regen is the canine treat stem cell activator. PawPa Regen supports anti-aging and wellness. Its other products include MyndMed and Wynovia. MyndMed is designed to optimize multiple neurotransmitter systems and neuroprotective pathways.